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Abstract
Purpose – A range of strategies to improve pharmaceutical care has been implemented by population health
management (PHM) initiatives. However, which strategies generate the desired outcomes is largely unknown.
The purpose of this paper is to identify guiding principles underlying collaborative strategies to improve
pharmaceutical care and the contextual factors and mechanisms through which these principles operate.
Design/methodology/approach – The evaluation was informed by a realist methodology examining the
links between PHM strategies, their outcomes and the contexts and mechanisms by which these strategies
operate. Guiding principles were identified by grouping context-specific strategies with specific outcomes.
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Findings – In total, ten guiding principles were identified: create agreement and commitment based on a
long-term vision; foster cooperation and representation at the board level; use layered governance structures;
create awareness at all levels; enable interpersonal links at all levels; create learning environments; organize
shared responsibility; adjust financial strategies to market contexts; organize mutual gains; and align regional
agreements with national policies and regulations. Contextual factors such as shared savings influenced the
effectiveness of the guiding principles. Mechanisms by which these guiding principles operate were, for
instance, fostering trust and creating a shared sense of the problem.
Practical implications – The guiding principles highlight how collaboration can be stimulated to
improve pharmaceutical care while taking into account local constraints and possibilities. The
interdependency of these principles necessitates effectuating them together in order to realize the best
possible improvements and outcomes.
Originality/value – This is the first study using a realist approach to understand the guiding principles
underlying collaboration to improve pharmaceutical care.
Keywords Health care, Governance, Qualitative research, Strategy, Knowledge sharing, Pharmaceuticals
Paper type Research paper
Background
In order to provide high quality care while keeping health care systems affordable
and accessible, many countries are moving toward a population-based approach.
The assumption underlying a population-based approach is that to achieve better
population health and quality of care and a reduction in cost growth (Triple Aim (TA);
Berwick et al., 2008), collaboration is needed within and across public health, health care,
social care and community services (Alderwick et al., 2015). In Western countries, initiatives,
often referred to as population health management (PHM) initiatives, have emerged to close
the gap between health and community services (Steenkamer et al., 2017). For example, in
the USA, accountable care communities and private sector accountable care organizations
work together in multisector initiatives designed to improve population health in
communities and neighborhoods (Alley et al., 2016). PHM initiatives have also emerged
in the Netherlands. In 2013, the Dutch Ministry of Health, Welfare and Sport designated
several of these initiatives as pioneer sites (Drewes et al., 2016). The pioneer sites are
monitored and evaluated by the Dutch Monitor of Pioneer sites Population Management of
the Dutch National Institute for Public Health and the Environment (Struijs et al., 2015).
These initiatives, serving over 2 million people, represent partnerships between health care
insurance companies, primary care groups, hospitals, municipalities and community-based
organizations, including regional patient organizations. All initiatives aim to improve health
and provide better care at lower costs for the regional population by bridging clinical and
community services ( Drewes et al., 2016). The pioneer sites started in 2013 with both
care-related and pre-conditional interventions such as the organization of a governance
structure for, for example, the development of a shared agenda and coordination of activities
and communication.
Improving pharmaceutical care was one of the first subjects addressed within the
monitored Dutch PHM initiatives. In recent years, health care insurance companies had tried
different policies, such as outcome-based funding for effective prescription of medicine by
general practitioners, in an attempt to improve the quality of pharmaceutical care and to
control the cost of medicines. However, the expenditure on pharmaceutical care barely
dropped (Batenburg et al., 2015). Moreover, considerable regional variation remained such
as regional variation in prescription rates of expensive drugs and regional variation in
adherence to medical guidelines (Lambooij et al., 2016). Possible explanations for these
differences were amongst others the lack of transmural agreements between hospitals and
primary care organizations (Kerpershoek et al., 2012). Such an agreement provides, for
example, clarity about roles and responsibilities between general practitioners, medical
specialists and pharmacists with regard to the pharmaceutical management of patients and
contributes to the exchange of pharmaceutical expertise (Kerpershoek et al., 2012;
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Snyder et al., 2010). Also doctors were not always aware of the cost of medicine or neither
took costs into account in their decision making with regard to what drugs to prescribe, nor
were doctors always aware of what drugs were covered in what formulary (Kerpershoek
et al., 2012). The PHM initiatives assumed that a coordinated intervention including
multidisciplinary collaboration aiming to promote safe use and efficient prescription of
medicine both by general practitioners and, in hospitals (extramural medication), would be
better able to achieve financial savings and improve quality of care. Therefore, the Dutch
PHM initiatives introduced a range of strategies to stimulate collaboration between medical
specialists, general practitioners, (hospital and community) pharmacists and regional
patient organizations such as joint development of a pharmaceutical formulary. Besides, in
their overall aim to bridge prevention, care and welfare in the upcoming years,
PHM initiatives expected to build upon the new structures and arrangements (e.g. new work
groups for the development of new data technologies or shared shavings contracts) that
were developed and tested in this intervention for the first time.
In recent years, several strategies to improve collaboration on pharmaceutical care have
already been pointed out in the literature such as organizing face-to-face discussions
between doctors and pharmacists ( Joseph et al., 2017; Patel, 2016; Chui et al., 2014). However,
these strategies do not always work out as expected (Snyder et al., 2010; Joseph et al., 2017;
Chui et al., 2014). Research has shown that depending on the circumstances in which
strategies are implemented, and the motivations of people and organizations to act upon the
opportunities and resources that strategies offer in these circumstances, the same strategy
can have different results (Pawson, 2013). In general, studies have insufficiently taken into
account both contextual and motivational factors that contribute to the explanation of how
and why collaborative strategies achieved their results (Saul et al., 2013; Glasgow et al., 2012;
Greenhalgh et al., 2004). With regard to pharmaceutical care, no studies could be found
describing both the circumstances in which collaborative strategies were implemented and
the motivational factors that influence the outcomes of these strategies. Up till now, just one
study (Chui et al., 2014) analyzed the motivations of physicians and pharmacists with regard
the developing and sustaining collaboration. However, this study did not include contextual
factors that influence motivations of people and organizations. Taking into account the
complexity of the various strategies, contextual factors and motivations of different
professionals and organizations, as revealed in the collaborative adaptive health network
(CAHN) framework (Steenkamer et al., 2018), is important to understand which strategies
work in which situations and how and why these strategies contribute to organizing
collaboration to improve pharmaceutical care. However, up till now, an insight into the
relationships between strategies, contextual factors, mechanisms and outcomes of strategies
with regard to pharmaceutical care is lacking.
Therefore, the aim of this study is to identify how and why specific strategies stimulate
collaboration in order to improve pharmaceutical care. More specifically, this study will
identify the guiding principles that highlight how collaboration can be stimulated to
improve pharmaceutical care while taking into account local constraints and possibilities.
Methods
This evaluation was informed by the realist evaluation method of Willis et al. (2016).
Traditional realist evaluations aim to provide an understanding of “what works, for
whom, in what context, to what extent and how and why it works to produce outcomes?”
(Pawson, 2013). As such, the underlying principles of a realist approach are the links
between respectively: strategies (S), contexts (C), mechanisms (M) and outcomes (O).
The main focus of traditional realist evaluations is on generating or testing theories by
focusing on how particular contexts (C) trigger changes in the reasoning and behavior of
human actors (mechanisms (M); Wong et al., 2016). Instead of providing a theory, those
PHM guiding
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working in complex systems such as the PHM initiatives benefit most from guiding
principles based on theory-driven, contextually relevant strategies (S) that are associated
with specific outcomes (O) (Saul et al., 2013; Willis et al., 2016). Therefore, in contrast to
traditional realist reviews, the focus of this study was to point out the guiding principles and
the contexts and mechanisms by which these principles operate. Strategies are considered a
directed course of action that produce (desired) proximal, intermediate or final (process)
outcomes (McKeown, 2011). In our study, strategies are related to collaboration to improve
pharmaceutical care. Contexts are the different sociocultural, relational, economic, political
and historical configuration such as financial incentives or the history of the working
relationship (Glasgow et al., 2012). Mechanisms are the changes in the behavior or reasoning
of stakeholders triggered by changes in contexts like a growing sense of urgency of PHM
initiatives to improve pharmaceutical care.
This realist evaluation included several iterative stages: engagement of experts and
reference panels; data collection; and analyzing, synthesizing and interpretation of data. As
per realist evaluations’ methodology and in line with the RAMESES standards (Wong et al.,
2013), an expert and reference panel were engaged to ensure the evaluation was grounded in
the needs of the knowledge user and was consistent with current international expertise and
knowledge. The research team consisted of experts with national and international experience
and expertise in health system transformation and PHM. As a reference panel, the existing
Advisory Committee of the Dutch Monitor of Pioneer sites Population Management was
involved, including scientists and representatives of the Ministry of Health, Welfare and
Sports and of the PHM initiatives. In addition, a local reference panel was involved, consisting
of representatives of all seven PHM initiatives included in this review. In a kick-off meeting,
the research question, methodology and the CAHN framework (Steenkamer et al., 2018) to be
used for the analysis and synthesis of the data in this study were presented to the experts and
the local reference panel. The framework is based on an international inventory of the
literature on collaborative efforts cross-linking public health, health care and social and
community services to achieve the TA. The framework describes eight components (relations,
social forces, accountability, leadership, resources, finance, regulations and market).
Most components consist of three or more subcomponents. The (sub)components contain
the available theories and insights into the relationships between strategies, contextual
factors, mechanisms and outcomes of collaborative efforts cross-linking public health, health
care, social care and community services. The experts and local references agreed to the
research question, methodology and framework used in this study.
Between January 2016 and June 2016, data were collected during focus groups and
individual interviews of seven PHM initiatives in total. Focus groups were held in 4 PHM
initiatives with a total of 26 participants (general practitioners, pharmacists, medical
specialists (internal medicine, and cardiology), representatives of health care insurers and
patient organizations, and project and program managers). For three PHM initiatives,
individual interviews were held with a program manager or pharmacist (three interviews in
total) (an overview of the participants and information about the structure and organization
of the PHM initiatives and the pharmaceutical interventions is available on request).
To become familiar with the intervention improving pharmaceutical care and the PHM
region, the authors collected additional data such as pharmaceutical toolkits describing the
agreements and procedures regarding the new multidisciplinary approach to
pharmaceutical care, which were developed by the PHM initiatives. Also during the
kick-off meeting, participants were asked to share their experiences with the new strategies
PHM initiatives practiced.
A semi-structured interview guide was used to support the interview process (available
on request). At two points during the interview, all interviewees were asked to write down
their lessons regarding which strategies worked or failed in improving collaboration on
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pharmaceutical care. The first time was at the start of the interview enabling the discussion
about these lessons during the focus group or during the individual interview. The second
time was after the presentation of the eight components of the CAHN framework, enabling
interviewees to add lessons that came to mind upon viewing the eight components.
All lessons were discussed, and additional information regarding strategies, contextual
factors, underlying mechanisms and outcomes were retrieved during the interviews.
The interviews were audio recorded and transcribed verbatim.
In realist evaluations, analysis, synthesis and interpretation of the data tend to occur
alongside each other during the evaluation process (Pawson, 2006). Data analysis of the
data collected during the interviews was done using Microsoft Excel® and the MAXQDA
software. Using MAXQDA, texts containing information with regard to links between
context-specific strategies, contextual factors, mechanisms and outcomes related to the
context specific strategies were given a codename reflecting the essence of the passage.
Strategies were identified by descriptions of courses of action at the board or operational
level. Outcomes of strategies were identified by descriptions of unintended or intended
proximal, intermediate or final process results of collaborative strategies to improve
pharmaceutical care. Contexts in which the strategy was implemented were recognized by
descriptions of circumstantial factors on a local, regional or national level. Mechanisms
were recognized by descriptions of changes in the reasoning or the way stakeholders
acted upon the opportunities and resources the strategies offered in the specific context.
The quality of the relations between the elements of each link was guided by the
requirements of a realist review (Wong et al., 2013). The codes were arranged in MAXQDA
along the according (sub)components of the CAHN framework. Next, the overview in
MAXQDA of the links between strategies, contexts, mechanisms and outcomes per (sub)
component was converted into a Microsoft Excel® spreadsheet. Furthermore, the name
from the PHM initiative from which each link originated was added to every link. This
spreadsheet was used to identify the guiding principles. Per (sub)component, context-
specific strategies related to specific outcomes that were put forward by at least two PHM
initiatives were grouped into guiding principles. The research team shared the evidence
gathered for each guiding principle on a regular basis. As a result, the team formed an
evolving understanding of the contextual factors enabling or constraining the likelihood
of the guiding principles to be effective and the mechanisms by which the specific
outcomes of the guiding principles were reached.
The research team and reference panels reflected and commented upon the whole
research process. In addition, a researcher outside the research team (LB) verified the
analysis, synthesis and interpretation process. Furthermore, results were presented and
discussed during a feedback meeting with representatives of four of the participating PHM
initiatives and one PHM initiative that did not participate in this study. Finally, based on
this feedback, the guiding principles and accompanying contextual factors and mechanisms
were debated and refined within the research team.
Ethics approval
Ethics approval from the Psychological Ethical Review Committee at Tilburg University
(EC-2015.54) was received in October 2015.
Results
A total of ten guiding principles enhancing collaboration to improve pharmaceutical care
were identified. The strategies as well as the contexts and mechanisms by which these
guiding principles operate are shown in Table I. Some strategies, contexts and mechanisms
appear across different guiding principles. This illustrates how particular strategies
influence collaboration to improve pharmaceutical care in multiple ways. The next section
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Table I.
Guiding principles
including strategies,
contexts and
mechanisms
underlying
collaboration to
improve
pharmaceutical care
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elaborates on the guiding principles. First, per guiding principles, groups of strategies
related to specific outcomes will be described. Next, we give an account of these strategies,
the contextual factors enabling or constraining the effectiveness of these strategies and the
mechanisms by which outcomes are reached.
Guiding principles, strategies, contextual factors and underlying mechanisms
Guiding principle 1: create agreement and commitment based on a long-term vision. PHM
initiatives implemented two different strategies to organize agreement on and commitment
to a coordinated intervention including multidisciplinary collaboration regarding
pharmaceutical care (see Table I). First, all PHM initiatives invited a number of regional
stakeholders within the care sector to engage in improving pharmaceutical care. Predating
the PHM initiatives, too often interventions were undertaken by single organizations and
professionals (hospitals, general practitioners) with limited benefits to the target population,
let alone lower pharmaceutical costs. This contextual factor induced a sense of urgency
among regional stakeholders to organize a coalition of the willing to improve
pharmaceutical care in line with the TA. Another contextual factor was dissatisfaction
among stakeholders with health care insurance companies purchasing care products for the
lowest negotiated price on a yearly basis. This purchasing process elicited competition
among providers in the regional market, which was already characterized by a history of
mono-disciplinary interventions. This induced readiness for change in stakeholders for a
regional multidisciplinary approach toward pharmaceutical care based on a long-term
vision, as is reflected in the following quote:
[…] Many single projects [aiming to improve pharmacy care] in the past have failed, and now we
aim for sustainable regional collaboration based on health, quality and costs. So there is a vision
behind it which is the driving force behind everything we are going to do in the future (I2, health
care insurer representative).
Second, five PHM initiatives facilitated stakeholders to jointly develop a business plan for
substituting brand for generic medicines including a new financial incentive model
(e.g. shared-savings contract). A contextual factor enabling this strategy was a growing
sense of urgency mainly from the health care insurance companies to counter ongoing high
prescriptions of expensive drugs with little effect on health improvement. For the providers,
this growing sense of urgency was also fueled by the fact that failing to cooperate would
have negative financial consequences (see also guiding principle 7). This contextual factor
induced feelings of problem ownership and encouraged stakeholders to reach agreement
and commitment regarding lowering of prescription rates of expensive drugs and changes
in ways of working, capacity and finance. However, in four PHM initiatives, other
contextual factors such as corporate restructuring of stakeholders’ organizations hindered
the process of agenda setting and the timing of engagement of individual organizations.
Consideration of strategic, financial and substantive arguments at the board level of
participating organizations took more time. In these organizations, prioritizing between
what they regarded as a small-scale project and their own restructuring process delayed the
process of gaining agreement and commitment to multidisciplinary collaboration on
pharmaceutical care.
Guiding principle 2: foster cooperation and representation at board level. PHM initiatives
fostered cooperation and representation at steering committee level to encourage leaders of
regional care groups, hospitals and pharmacies to invest in multidisciplinary collaboration
on pharmaceutical care. This study identified two strategies. The first strategy was that
PHM initiatives sought opportunities to stimulate multidisciplinary collaboration ( five PHM
initiatives). Within the context of expected positive revenues gained through the
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introduction of shared savings contracts, this strategy enabled leaders to cooperate for three
reasons. First, leaders felt obliged to prove that a multidisciplinary approach to
pharmaceutical care could be successful. Given the historically disappointing results of a
mono-disciplinary approach to improve pharmaceutical care, multidisciplinary agreement
on lowering the prescription rates of expensive drugs and enhancement of drug safety
guaranteed these quick wins. Second, leaders reasoned that these quick wins could give
them the opportunity to create a financial buffer to support future projects within the PHM
initiatives. Lastly, they presumed that cooperation would increase the visibility of PHM
initiatives on a regional and national level.
The second strategy was installing the right people at the right time in the right place
(all PHM initiatives). PHM initiatives differed in the way they organized representation of
pharmacists depending on which knowledge (content or strategic) was needed during the
process. Pharmacists were represented in the steering committee of the PHM initiative
( four PHM initiatives), or regional legal entity (one PHM initiative). In addition, all PHM
initiatives organized representation of pharmacists at the project level, and some had an
additional steering group for this specific intervention:
[…] at an early stage, you often need representatives that are supported by their organizations and
have the capability to think strategically. After 3 or 4 meetings you also need knowledge […] this
issue is insufficiently recognized […] (I3, pharmacist).
Representation of pharmacists at the level of the steering committee of PHM initiatives
increased the possibility to channel and discuss problems and to adjust policy regarding
pharmaceutical care. Consequently, the involvement of pharmacists in other projects of the
PHM initiatives increased. However, pharmacists felt less involved when only represented
on a lower level. On the other hand, representation in a project group led to pharmacists
investing more time and in-depth knowledge in the project in comparison to participation in
the steering committee. The regional legal entity combined the best of both worlds:
generating more involvement and visibility of pharmacists in regional projects and more
investment of time and expertise.
Guiding principle 3: use the layered governance structure (steering committee and
operational level). All PHM initiatives used a layered governance structure for escalation and
facilitation purposes to direct and enable multidisciplinary collaboration. The governance
structure of most PHM initiatives comprises a steering committee, one or more working
groups and sometimes an executive or management committee. Two strategies were
identified. First, all PHM initiatives made conscious use of information within the layered
governance structure for escalation or facilitation purposes. This strategy was profitable
within the context of solving problems for which additional background information or
exchange of information at a certain level within the governance structure was needed.
Managers, for instance, learned more about the professional, organizational or regional
sensitivities and interests during steering committee meetings. Consciously using
information for escalation and facilitation purposes helped to generate commitment to
modify prescription behavior and adjust ways of working in line with the agreed upon
pharmaceutical protocol.
Second, all PHM initiatives made conscious use of the skills and influencing power of
PHM managers and professional experts for escalation or facilitation purposes within the
layered governance structure. In situations where professionals had different paces of
adjusting to the new multidisciplinary working processes, this strategy worked positively
for those colleagues who had worked alongside each other for years. By having PHM
managers confront professionals on their pace of adjustment to the new ways of working,
instead of having colleagues confronting each other, it was ensured that professional
relationships were not put under pressure. In contexts in which stakeholders had different
PHM guiding
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interests and levels of commitment within the layered governance structure, the same
strategy generated confidence mechanisms among stakeholders. Stakeholders were of
the opinion that PHMmanagers and professional experts such as medical specialists who, at
the same time, hold a professorship were more capable of highlighting the differences and
similarities in interests and commitment due to their so-called independent position within
the layered governance structure. They were assumed to know the different organizational
cultures and to have good communication and persuasion skills. The contribution of PHM
managers and experts’ ability to enhance confidence levels was an important precondition
to direct PHM initiatives toward multidisciplinary collaboration and thus for launching the
pharmacy intervention (six PHM initiatives).
Guiding principle 4: create awareness at all levels. Six PHM initiatives applied three
strategies to ensure awareness at all levels about the need to improve pharmaceutical care,
thus allowing the development of new pharmaceutical protocols and working processes.
First, PHM initiatives organized continuous interaction and communication between health
care insurance companies, regional care providers and patient organizations. The managers
played an important role in the execution of this strategy by serving as a link between
parties and by organizing discussions (see also guiding principles 3-7). A contextual factor
enabling this strategy was the development of a pharmacy toolkit, which enabled
discussions regarding guidelines and scientific knowledge, and health care insurance claims
data. These discussions generated several mechanisms. First of all, they enabled the
re-examination of existing pharmacotherapies with the intention of reducing costs without
losing the quality of care. Furthermore, these discussions generated taking into account
multiple medical guidelines (general practitioners and various medical specialists), which,
although evidence-based, sometimes contradicted each other:
For example with regard to the lipid level, there is a difference between general practitioners and
cardiologists with respect to the cut-off values that should be pursued (I7, cardiologist).
Discussing differences made stakeholders more aware of each other’s point of view. Despite
these differences, consensus regarding new pharmaceutical protocols was reached. Lastly,
the discussions also stimulated the re-examination of existing working processes and
professional roles in order to modify them in line with the new multidisciplinary pharmacy
protocol ( five PHM initiatives). For example, agreements were reached about the time frame
within which patients had to be informed, the number of substitution consultations that
should be executed and who was responsible for drafting the pharmaceutical advices and
for the substitution consultations:
[…] differences become transparent and negotiable during discussion. Sometimes we reached an
agreement, sometimes not. Most of the time consensus was reached. Also negative emotions
became apparent. In the past, differences were often not understood, people felt that others did not
cooperate but did not know why (I15, project manager).
A second strategy was making use of existing consultation situations. An enabling
contextual factor of this strategy was the pre-existing quality of consultations between
medical specialists, general practitioners, pharmacists, physician assistants and patients
(three PHM initiatives). Joining existing consultation situations in which people already
knew and trusted each other created a safe situation for discussing medication policies and
ways of working. Consequently, creating awareness for needed changes was easier than in
situations where trust levels were low (three PHM initiatives).
A third strategy in the same context generated similar mechanisms. PHM initiatives
developed information leaflets and made information available in waiting rooms to support
communication with patients of the new medication policy. Discussing this information in a
trusted environment increased awareness of patients that a generic drug would have the
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same, or even better results with lower costs, and reduced feelings of mistrust toward the
new drug efficacy ( five PHM initiatives).
Guiding principle 5: enable interpersonal links at all levels. PHM initiatives organized
interpersonal links to establish openness to (new) knowledge, ideas and a more
multidisciplinary perspective regarding pharmaceutical care to support changes in norms,
values and ways of working. This study recognized three strategies and one enabling
contextual factor influencing these three strategies. This contextual factor was the already
increased collaboration within primary care and between primary and secondary care.
For instance, for years most general practitioners and pharmacists were engaged in
pharmacotherapy consultation groups and knew each other on a personal level. Two
strategies were identified. The first strategy of PHM initiatives was joining these already
existing consultations ( five PHM initiatives) (see also guiding principle 4) and second was
organizing regional multidisciplinary meetings to share best practices or the pharmacy
protocols that were developed ( four PHM initiatives).
The third strategy PHM initiatives undertook was to include a range of different
professionals in these regional meetings. These strategies enhanced trust, recognition and
acknowledgment of each other’s contribution and scientific knowledge (two PHM initiatives).
In three PHM initiatives, continuous sharing of experiences in the region led to installment of a
regional multidisciplinary pharmaceutical committee (see also guiding principle 2).
Guiding principle 6: create a learning environment. PHM initiatives created a
learning environment that supported the use of measurements within a feedback loop
(plan-do-check-act). This study identified two strategies. First, PHM initiatives organized
data input and/or new tools to match the information needs of professionals (all PHM
initiatives). Until then, health care insurance claims data provided insufficient insight into
the degree of improvement of prescription practices due to, for example, a lack of a
historical overview and insufficient insight for general practitioners into repeat
prescriptions of medical specialists (all PHM initiatives). Also the time frame within
which changes in prescriptions were reflected in the data and the level of feedback was
insufficient ( five PHM initiatives). These contextual factors enabled the strategy to
enhance motivation of professionals to engage in the feedback loop.
Second, to support data input and tool development, PHM initiatives organized capacity
and knowledge of data technology, data analysis and synthesizing data into meaningful
information. Information was seen as important in creating awareness of inefficient
pharmaceutical care. Insufficient capacity and knowledge put pressure on professionals and
health care insurance companies to establish either internal or external capacity and
knowledge to support data input and tool development. The former meant either health
care insurance companies ( four PHM initiatives) or professionals themselves (one PHM
initiative) took the lead in organizing capacity and knowledge. Professional control led to an
immediate enhancement of the level and frequency of data feedback. Two PHM initiatives
organized external capacity and knowledge. In one of these PHM initiatives, this resulted in
the development of a business-intelligence tool that links selected data from pharmacy,
primary care and laboratory registries in order to track and decrease the use of high-cost,
low-quality services for specific diseases.
Guiding principle 7: organize shared responsibility. PHM organized shared responsibility
for multidisciplinary improvement of regional pharmacy care. This study recognized two
strategies. First, five PHM initiatives organized a new incentive design for multidisciplinary
responsibility to improve pharmaceutical care. Contextual factors enabling this strategy
were the fact that the old incentive design (e.g. separate incentives for general practitioners
and pharmacists) did not fit the new multidisciplinary agreement of PHM initiatives.
Also, leaders felt an urgent need to improve pharmaceutical care, as they were not pleased
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with negative financial incentives for not following the formulary (also see guiding
principle 1). In addition, leaders expected shared savings to encourage multidisciplinary
responsibility by letting stakeholders share realized savings that were associated with
certain results (e.g. X% brand converted into generic within certain time frame). However, a
constraining contextual factor of the strategy was the difference in basic principles of
professionals and organizations that became apparent during the development of the
pharmacy protocol, such as differences in cut-off values and scores or setting of
the benchmark (also see guiding principles 4 and 6). For instance, teaching hospitals only
wanted to be benchmarked with other teaching hospitals, as their patient population is very
different from community hospitals. PHM initiatives took these differences into account
while designing these new incentive designs.
The second strategy was to organize an adherence design, based on social forces like
peer reviewing in which general practitioners, pharmacists and medical specialists
discussed each other’s results. Because stakeholders were dissatisfied with pre-existing
individual and regional prescription rates of expensive drugs, peer reviewing induced a
shift to multidisciplinary accountability resulting in a higher participation rate of providers
than mono-disciplinary accountability ( five PHM initiatives). Also, peer reviewing in a
multidisciplinary context prompted strong feelings of motivation for achieving
better performances, especially if stakeholders already had positive experiences with the
plan-do-check-act cycle ( five PHM initiatives).
Guiding principle 8: adjust financial strategies to the market context. PHM initiatives
implemented two financial strategies to strive for the best pharmacy therapy for the lowest
price, given the market context. First, two PHM initiatives took into account market factors
and trends of pharmaceutical products such as prices, applicability of products and
expiration dates of patents to define the pharmacy formulary. On the basis of this
formulary, health care insurance companies negotiated with manufacturers on the basis of
efficiency and quality:
If you look at the price of Spiriva for COPD patients, sixty percent of the low budget medication is
Spiriva […]. But the patent of Spiriva expires this year […] Now the costs are 80 or 90 euros and
this can drop to a couple of euros […] (I12, pharmacist).
The insurance companies successfully challenged manufacturers to lower pricing rates per
serving in order for them to be included into the formulary. Although the formulary gave
financial and qualitative advantages, it was also criticized for reducing the freedom of
choice of medicine:
For asthma/COPD products, we looked per interchangeable groups of medicines on the basis of
qualitative criteria. How medicine should be applied played an important role in this choice.
[…] And now the insurer is asking the pharmaceutical market to react on this formulary.
The manufacturers don’t know the formulary content, but were asked to provide the best possible
price. If manufacturers are lower in price than the ones on the formulary, and the quality of the
medicine does not differ much, then such a manufacturer can still end up on the formulary. In this
way we try to combine quality with efficiency (I15, program manager).
Second, two PHM initiatives organized financial insight to support treatment options,
starting with people with multimorbidity. Within the context of striving for the best
pharmaceutical therapy for the lowest price, this strategy induced deliberate use of financial
outcomes and combining this data with clinical data and patient preferences:
For CVRM you can make estimates how much risk you want to take. […] You cannot change
everything at once, so you would like to discuss with patients ‘if you lose five kilos the chance of
getting a heart attack will be reduced with 10%, and if you stop smoking then it will drop with another
30%, and when you take your medicine the chances will reduce even further with another 5%.
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So what is feasible for you? By bringing together data with regard to clinical outcomes, patient
preferences and financial data e.g. option 1 would be the cheapest solution and option 3 would lead to a
financial break even (I29, program manager).
As a result, PHM initiatives were capable of weighing individual treatment options as well
as improving health care purchasing processes in the regional market (two PHM initiatives).
Although combining data raised political concern related to privacy laws and regulations,
one PHM initiative derived legitimacy for the experiment based on support expressed by a
visiting political delegate.
Guiding principle 9: organize mutual gains. PHM initiatives organized mutual gains to
develop a financial buffer and put the initiative “on the map.”
This study identified two strategies. The first strategy of PHM initiatives was to focus on
“low-hanging fruit” to gain quick wins. Because leaders expected positive revenues gained
through the introduction of shared savings contracts, several distribution scenarios of
potential savings were under debate at the start of the intervention. One of these scenarios
was directing all savings back to the professionals executing the intervention (see also
guiding principles 2 and 7). However, discussions in society at large about unequal
distribution of bonuses influenced the debate. Three PHM initiatives were motivated to
funnel net savings back to serve as a financial buffer for future interventions that would
benefit the health of the regional community.
The second strategy of PHM initiatives was to enhance the visibility of the PHM
initiatives (see also guiding principle 2). Improving pharmaceutical care was just the first
intervention of a growing regional PHM program as initiatives wanted to address medical
and social determinants of health of the regional community. The pressure of PHM
initiatives to work toward a comprehensive regional program led to a focus on achieving
financial wins ( four PHM initiatives). These quick wins not only symbolized successful
regional multidisciplinary collaboration, but also the potential of PHM initiatives to continue
their journey and enhance their regional and national visibility.
Guiding principle 10: align regional agreements with national policies and regulations.
PHM initiatives implemented two strategies. First, PHM initiatives indicated at the earliest
possible moment when existing regulations did not match new regional agreements.
Four PHM initiatives stated that a constraining contextual factor for this strategy was the
“preference policy” of health care insurance companies. Although health care insurance
companies agreed to the regional pharmaceutical formulary of PHM initiatives, in hindsight,
one medication group did not match the national preference policy of insurance companies.
This contextual factor led to risk factors at the level of the treatment relationship, as PHM
initiatives assumed all medicines within the formulary would be reimbursed. Providers
sometimes had to deal with dissatisfaction of patients due to the miscommunication about
reimbursement of medicine. Furthermore, PHM initiatives risked damaging the
accountability relationship between the insurance company and the initiatives. Although,
eventually, the national preference policy was adjusted to the regional policy regarding the
aforementioned medication group, providers were only reimbursed from this moment
onwards. Other constraining contextual factors were the existing walls regarding funding
systems between sectors and disciplines:
Although we have made agreements to provide integrated care, we face the current fragmented
funding streams. So, integrated agreements were unraveled into separate pieces in order for them to
be separately funded in line with the existing system. This is not easy, it took tremendous effort to
get organizations support the integrated regional approach (I6, project manager).
This factor led to the unraveling of the multidisciplinary agreements to adhere to current
financial systems.
PHM guiding
principles
D
ow
nl
oa
de
d 
by
 E
RA
SM
U
S 
U
N
IV
ER
SI
TY
 R
O
TT
ER
D
A
M
 A
t 2
3:
28
 0
4 
A
pr
il 
20
18
 (P
T)
Furthermore, as health care insurance companies tended to stick to their own contract
and not follow the contract of the other health care insurers in the same region, the second
strategy of PHM initiatives was to reduce ambiguity with regard to which policy, and thus
which contract, was preferred in the region (all PHM initiatives). This strategy was
especially important when there were two or more health care insurers with a similar or at
least substantial market share in PHM regions. Regulations about contracting of insurance
companies were regarded by leaders of PHM initiatives as a constraining contextual factor
as insurance companies could contract care provision as they saw fit. This factor led PHM
initiatives to require clarity of the non-preferred insurance company at the earliest possible
stage to reduce uncertainty in financial revenues, reduce additional administrative burdens
and reduce the risk of lack of support for the intervention (all PHM initiatives).
Discussion
This study identified ten guiding principles for the organization of regional collaboration to
improve pharmaceutical care in line with the TA goals: create agreement and commitment
based on a long-term vision; foster cooperation and representation at board level; use the
layered governance structure; create awareness at all levels; enable interpersonal links at all
levels; create a learning environment; organize shared responsibility; adjust financial
strategies to the market context; organize mutual gains; and align regional agreements with
national policies and regulations. The strategies underlying each guiding principle interact
with various contextual factors and thereby trigger different mechanisms that influence
collaboration to improve pharmaceutical care. Furthermore, the guiding principles are
interdependent. Therefore, it is necessary to develop and implement them together in order
to realize the greatest improvements and outcomes.
Reflecting on the guiding principles, two types of guiding principles can be identified: guiding
principles 1-5 predominantly represent the people management side of improving collaboration.
Guiding principles 6-10 relate predominantly to the technical conditions of improving
collaboration. Both types of guiding principles are interdependent as is in line with previous
work (Tsasis et al., 2012; D’amour et al., 2008). The current study, for instance, revealed that the
success of organizing shared accountability arrangements (a mainly technical guiding principle)
highly depended upon getting people on board and commit to the collaborative initiative, getting
people more aware of why and what changes were needed (both guiding principles that mainly
address the people management side), and getting people to adopt a learning environment
(a mainly technical guiding principle) that supports multidisciplinary accountability.
For guiding principles 1-5 to be effective, it is important that regional stakeholders get
to know each other and gain awareness of shared regional problems in order to be able to
develop a long-term regional vision. This requires contexts highlighting mutual dependence of
regional stakeholders which is in line with McMillan and Chavis (1986). These authors
revealed that mutual dependence is essential to create a sustainable sense of community:
membership, shared emotional connection, integration and fulfillment of needs, and influence.
In contrast to McMillan and Chavis, who referred to the need for leadership and power to
influence the participation of stakeholders, our study indicated that building interpersonal
links based on feelings of trust, openness to new perspectives, face-to-face conversations, and
recognition and acknowledgment of each other’s work reinforced bidirectional influence
among stakeholders. These factors are in line with the model of interpersonal relations of
Lanham et al. (2009). Also, adding to Schein (2010), who mentioned that cooperation on the
operational level is based on a feeling of security, it was shown in the present study that the
same holds true on board level. The expected revenues of the shared savings contracts
enhanced a sense of safety for change, which contributed to the cooperation on the board level
of PHM initiatives. Creating opportunities such as expected financial revenues of shared
savings contributed to multidisciplinary responsibility for improvement of pharmaceutical
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care and could lead to greater probability of scale-up and visibility of the PHM initiatives.
Furthermore, guiding principles 1-5 resonate with the literature highlighting the importance of
stepwise engagement of stakeholders in the context of reform based on a long-term vision
(e.g. Breton et al., 2010; Ovseiko et al., 2014; Pate et al., 2010). Our findings are in agreement
with research on the cooperation of board members and shared leadership roles distributed
across layered governance structures, which reduce disconnection between the board,
management and the operational level (e.g. Buchanan et al., 2007; Best et al., 2012; Greenhalgh
et al., 2012). Lastly, our findings resonate with the literature on social connection important for
creating awareness of problems and possible solutions (Scott et al., 2000), and creating ways
for socially reinforcing changes in working practices (Wilson, 2010).
Guiding principles 6-10 are consistent with the literature on the importance of learning
environments in times when roles and working practices, professional and organizational status
are in flux (e.g. Scott et al., 2000; Tajfel, 1972; Fong et al., 2007). Our study showed that not only
problem awareness, the quality of the relationship and the amount of trust between organizations
and professionals are important social forces that induce shared responsibility (Scott et al., 2000;
Chreim et al., 2010; Wilson, 2010), but that also positive experiences within the organized learning
environment helped negate resistance to change and enabled sharing multidisciplinary
responsibility. Therefore, together, these elements could be regarded as a substitute for formal
control mechanisms. The guiding principles also resonate with the competition literature on
prices and quality (Charlesworth and Cooper, 2011). Additionally, alternative funding models
have been introduced in several PHM initiatives. This study identified that the shared savings
contracts have brought first experiences and goodwill within the PHM initiatives to experiment
with new funding models that encourage multidisciplinary responsibility. Shared savings
contracts might help modify underlying care patterns. Moreover, the relationship between the
health care insurance companies and providers seems crucial for the organization of shared gains
and the success of reforms in payment methods and thus the sustainability of the reform of
pharmaceutical care. This is in line with previous work by Song et al. (2014) and Petsoulas
et al. (2011). Furthermore, in accordance with the work of Liddy et al. (2013) and Kingdon (1995),
changes in purchasing processes and preference policies of health care insurance companies were
based on two-way exchanges between national policies and regional practice, which helped to
create windows for change. Health care insurers, as key partners in the PHM initiatives, adjusted
for instance national preference policies based on evidence emerging from the PHM initiatives
that the new pharmaceutical formulary was the example of best practice. Lastly, PHM initiatives
derived legitimacy for linking selected data to help individual patients to manage their own care,
based on support expressed by a visiting political delegate. However, the lack of political
acknowledgment of legal tensions related to privacy laws and regulations could hinder the
progress of PHM initiatives (Kingdon, 1995), especially as experiments of combining data are
technically feasible, and anticipates future constraints of data exchange as PHM initiatives
engage in integrating clinical and community services.
This study adopted an evaluation method based on realist principles. This approach
provides insights that other forms of synthesizing evidence would not have given
(Willis et al., 2016). Furthermore, the engagement of experts and knowledge users from the
beginning ensured that this study is rooted in the activities of those actually undertaking
collaborative efforts to achieve results in line with the TA. Moreover, ongoing engagement
of experts and reference panels in understanding and refining the data renders a degree of
confidence in the reliability of our analysis. However, this study has limitations. First,
while our approach was systematic and rigorous, our results cannot be regarded as an
exhaustive list of elements that influence the process of organizing regional collaboration to
improve pharmaceutical care. On the contrary, the guiding principles identified in this study
are part of an ongoing process of sharing experiences and knowledge to advance our
understanding of “what strategies work in what context, and why these strategies work” to
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produce intended or unintended results. Second, the focus of this evaluation was on Dutch
pharmaceutical care. The results of this study will probably also be applicable in fields other
than those of improving pharmaceutical care as the guiding principles are based on all the
components of the CAHN framework. However, more insight is needed as not all of
the subcomponents as identified in the CAHN framework were addressed (Steenkamer
et al., 2018). The reason for this can partly be attributed to the fact that enhancing
collaboration to improve pharmaceutical care only concerned the care sector while CAHN
contains the (sub)components that influence collaboration across the continuum of public
health, health care, social care and community services.
Improving pharmaceutical care was in most Dutch PHM initiatives the first step in a large
program of change to build multiorganization and multisector collaborations designed to
address both medical and social determinants of health for regional populations. Elements
such as developing a multidisciplinary business plan, executing a multidisciplinary regional
approach, building and improving relationships, and experimenting with new forms of
funding such as shared savings contracts formed the basis for future regional collaboration to
align prevention, care and welfare services. The current PHM guiding principles provide
health system leaders and policy makers the necessary ingredients to choose strategies that
will lead to the intended outcomes given local, regional and national constraints and
opportunities. Considering the broader ambitions of PHM initiatives, future research in the
guiding principles, the underlying strategies and accompanying contexts and mechanisms by
which these guiding principles operate is necessary. The guiding principles are part of an
ongoing process of sharing knowledge and experiences. The Dutch Monitor of Pioneer Sites
Population Management will continue to monitor the Dutch PHM initiatives as they add new
stakeholders and populations and seek to grow their PHM programs. In addition, we will gain
insight into the learning experiences of four international PHM initiatives in 2017-2018. As a
result, we will be able to enrich the current guiding principles and identify new ones, and as
such will contribute to the international debate and learning with regard to the organization of
collaboration across public health, health care, social care and community services.
Conclusion
There are many factors stimulating collaboration to improve pharmaceutical care in the
Dutch PHM initiatives. The ten guiding principles identified in this study will support
health system leaders and policy makers to design, implement or improve strategies
fostering collaboration with the aim of improving pharmaceutical care. The guiding
principles must be developed and implemented together in order to realize the greatest
improvements and outcomes. Health system leaders can use these principles in the contexts
of their own regional setting and identify which activities and policies make most sense,
given regional constrictions and chances. Improving pharmaceutical care is an incremental
process. Continuous sharing of practices and understandings in implementing the guiding
principles will lead to improved pharmaceutical care.
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Appendix. The CAHN framework
The CAHN framework gives insight into how and why cross-sector collaborative strategies aiming to
achieve better population health and quality of care while reducing cost growth (TA) reached specific
outcomes, and the theories that contribute to these explanations. The framework contains eight
components: social forces, resources, finance, relations, regulations, market, leadership and
accountability (see Figure A1). Each component within the CAHN framework contains the
component specific links between the strategies aiming to achieve cross-sector collaboration and the
contextual factors in which these strategies are implemented, the mechanisms that explain why
specific outcomes were reached, given these contextual factors, and the outcomes of strategies.
Health system improvements
Inclusion criteria
Population
health
Quality
of care
Costs
Exclusion criteria
Relations
Collaborative Adaptive Health Network strategies
Responsibility The market  Resources Finance Leadership Regulations Social forces
1 Population
   identification
2 Triple aim
   assessment
5 Triple aim impact
   evaluation
4 Citizens centred
   interventions
3 Risk stratification and
   intervention selection
6 Quality
   improvement
   process
Figure A1.
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health networks
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Most components contain three or more subcomponents. In total, 38 subcomponents were identified.
All (sub)components are based on existing theories and models that originated from scientific areas
such as sociology, political science, cultural science, organizational science, economics and system
dynamics. As such, the CAHN framework summarizes the available theories and insights into the
relationships between strategies, contextual factors, mechanisms and outcomes of collaborative
strategies cross-linking public health, health care, social care and community services.
Figure A1 represents the evaluation model of the Dutch Monitor of Pioneer sites Population
Management of the Dutch National Institute for Public Health and the Environment (Struijs et al., 2015;
Drewes et al., 2015). The figure shows the eight components that influence the process of organizing
cross-sector collaboration to improve population health and quality of care while reducing the growth
of health care costs (TA). In addition, the figure shows the six steps of the PHM approach necessary to
implement population-centered TA interventions.
An overview of the representatives of the focus groups and interviews, the characteristics of the Dutch
PHM initiatives and pharmaceutical interventions, and the interview guideline are available upon request.
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